Compare Hasbro, Inc. (HAS) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Hasbro (HAS) trades at $90.75, down 0.31% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates robust profitability with 64.41% gross margins and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains positive with a $107.60 price target, representing 18.5% upside potential from current levels. Recent news highlights continued momentum in the Magic: The Gathering franchise and new product collaborations.

The outlook remains constructive with projected revenue growth to $5.0B in 2026 and net income recovery to $794M. Key risks include high debt levels at 59.09% debt-to-asset ratio and recent net income volatility. The stock offers value with reasonable P/E of 16.14x and strong institutional interest, though investors should monitor Q3 2026 earnings on October 20 for confirmation of the turnaround trajectory.

Inovio Pharmaceuticals (INO) trades at $1.155, up 2.21% today, while showing bearish technical signals with negative cash flow and substantial losses. The company's financials reveal minimal revenue of $65,340 against an $84.95 million net loss in 2025, with profitability metrics deeply negative. However, analyst sentiment is optimistic with a 58.83% buy rating and $2.75 consensus price target, driven by the upcoming FDA decision on INO-3107 for recurrent respiratory papillomatosis by October 30, 2026.

INO presents high-risk speculation with potential for significant upside if FDA approval is secured, but carries substantial fundamental weaknesses including persistent cash burn and negative margins. Investors should weigh the binary outcome of the regulatory decision against the company's challenging financial position and technical bearishness.